Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$28.00 | Pfpmp | Vnrcbnhry |
Guardant Health: Reducing FVE on Liquid Biopsy Leader With Long Road to Profitability
We are transferring coverage of Guardant Health, keeping our moat rating at none, and lowering our fair value estimate to $47 from $63 previously. This is driven by a slower projection of Shield’s revenue trajectory and partially offset by a more optimistic view of its Reveal franchise.